JAMA Oncology Archives
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
Vanderbilt research played key role in new lung screen guidelines
Mar. 18, 2021—The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening
Mar. 9, 2021—A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.
Criteria for lung cancer screens may be expanded
Jul. 23, 2020—The U.S. Preventive Services Task Force (USPSTF) is recommending two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
High fiber, yogurt diet associated with lower lung cancer risk
Oct. 28, 2019—A diet high in fiber and yogurt is associated with a reduced risk for lung cancer, according to a study by Vanderbilt University Medical Center researchers.
Study finds men have higher mortality rate after breast cancer diagnosis
Oct. 17, 2019—A new study shows men with breast cancer are more likely to die than their female counterparts, across all stages of disease.
Study backs genetic testing for all metastatic breast cancer patients
Sep. 5, 2019— by Tom Wilemon Genetic testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies, according to research published Aug. 29 in JAMA Oncology. In the study, 100 patients were tested regardless of whether they met the current National...
Immunotherapies linked to specific heart complications
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Study tracks incidence, timing of immunotherapy-related deaths
Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Cancer survival improvements vary by age, race
Feb. 26, 2015—Improvements in cancer diagnosis and treatment have led to longer survival for most cancer patients in the United States. However, the improvement in survival was substantially greater among younger patients and those who are white in most of the cancers studied, according to new research by Vanderbilt University investigators.
